肝癌多药耐药发生机制与监测标志物  

Mechanism of hepatocarcinoma multi-drug resistance and monitoring biomarkers

作　　者：顾星[1] 姚登福[1] 

机构地区：[1]南通大学临床医学研究中心,南通226001

出　　处：《南通大学学报（医学版）》2013年第4期315-318,共4页Journal of Nantong University(Medical sciences)

基　　金：国家国际科技合作专项(2013DFA32150);江苏省临床医学科技专项(BL2012053)

摘　　要：肝癌治疗强调个体化,在多种治疗方法中化疗仍然起着不可替代作用。肝癌具有先天和后天的多药耐药性,致化疗效果不理想,已成为治疗中急需解决的问题。本文述评了肝癌相关多药耐药产生机制与监测标志物的研究近况。It still plays an irreplaceable role that hepatocarcinoma therapy emphasizes individual, chemotherapy among many treatment methods. Its congenital and acquired multidrug resistance（MDR） leads to undesired effects of chemotherapy, which is the urgent problem required to be solved. This review summarizes recent studies of MDR mechanisms of hepatocarcinoma and its monitoring biomarkers.

关 键 词：肝癌 多药耐药 机制 标志物 

分 类 号：R735.7[医药卫生—肿瘤]